2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
AI Sentiment
Positive
7/10
as of 02-10-2026 3:46pm EST
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Upcoming Earnings Alert:
Get ready for potential market movements as Organon & Co. (OGN) prepares to release earnings report on 12 Feb 2026.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 1.8B | IPO Year: | N/A |
| Target Price: | $14.10 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.91 | EPS Growth: | -62.07 |
| 52 Week Low/High: | $6.18 - $17.23 | Next Earning Date: | 02-12-2026 |
| Revenue: | $6,301,000,000 | Revenue Growth: | -1.69% |
| Revenue Growth (this year): | -1.75% | Revenue Growth (next year): | -1.73% |
| P/E Ratio: | 4.14 | Index: | N/A |
| Free Cash Flow: | 777.0M | FCF Growth: | +4.02% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how OGN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.